Bruker (BRKR) News & Sentiment

Bruker has introduced the LUMOS II ILIM, an infrared microscope that uses QCL technology, aimed at pharmaceutical and life science research.

Bruker's latest technology, EpicIF, aims to improve the CellScape Precise Spatial Proteomics platform.

Bruker experienced strong revenue growth in the third quarter, even though the overall market conditions were weak.

Biognosys has announced that it will take part in the 23rd Human Proteome Organization (HUPO) World Congress, which will be held in Dresden, Germany, from October 20 to October 24.

Bruker's strong growth potential in its Nano segment is promising. However, negative changes in currency exchange rates may create difficulties.

Dublin, Sept. 20, 2024 (GLOBE NEWSWIRE) -- ResearchAndMarkets.com has released a new report titled "Dermatology Diagnostic Devices Market (2024 Edition)," which analyzes the market by device type, application, end-user, and region, providing insights and forecasts from 2020 to 2030. The report covers the growth of the Global Dermatology Diagnostic Devices market, which grew at a compound annual growth rate (CAGR) of 10.29% from 2020 to 2023, reaching a value of USD 7.57 billion in 2023. It is projected that the market will grow to USD 17.65 billion by 2030.

Bruker (BRKR) shared its earnings report 30 days ago. What can we expect for the stock moving forward?

BRKR shows strong growth potential in its key areas, which is promising. However, economic issues and competition may create difficulties.

Biognosys has partnered with Alamar Biosciences to offer NULISA multiplex assay services for biopharma research. Their NULISAseq™ CNS Disease and Inflammation panels are now available as a contract research service from their advanced proteomics facility in Europe. This combination of NULISA assays and TrueDiscovery® mass spectrometry provides comprehensive solutions for plasma proteomics, making Biognosys a leader in next-generation proteomics for drug discovery and development.